We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Kazia Therapeutics Limited | ASX:KZA | Australian Stock Exchange | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.08 | 0.077 | 0.083 | 0.00 | 01:00:00 |
By Colin Kellaher
U.S.-listed shares of Kazia Therapeutics jumped in premarket trading Thursday after the Australian biotechnology company said the U.S. Food and Drug Administration granted a second fast-track designation to its lead program, paxalisib, in certain brain-cancer patients.
The Sydney-based company said the latest designation covers paxalisib for the treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy.
The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs.
Kazia previously won FDA fast-track designation for paxalisib in glioblastoma, an aggressive type of brain tumor, in August 2020.
Kazia's U.S.-listed shares, which closed Wednesday at $1.17, were recently up nearly 26% to $1.47 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 06, 2023 07:36 ET (11:36 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Kazia Therapeutics Chart |
1 Month Kazia Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions